183 related articles for article (PubMed ID: 21715107)
21. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
[TBL] [Abstract][Full Text] [Related]
22. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.
Bisaga A; Aharonovich E; Cheng WY; Levin FR; Mariani JJ; Raby WN; Nunes EV
Drug Alcohol Depend; 2010 Sep; 111(1-2):97-104. PubMed ID: 20537812
[TBL] [Abstract][Full Text] [Related]
23. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
24. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
25. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
Gerra G; Fantoma A; Zaimovic A
J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
[TBL] [Abstract][Full Text] [Related]
26. Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Tsoy M; Wahlgren V; Burakov A; Masalov D; Romanova TN; Palatkin V; Tyurina A; Yaroslavtseva T; Sinha R; Kosten TR
Drug Alcohol Depend; 2013 Oct; 132(3):674-80. PubMed ID: 23683793
[TBL] [Abstract][Full Text] [Related]
27. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
28. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
31. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Collins ED; Kleber HD; Whittington RA; Heitler NE
JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
[TBL] [Abstract][Full Text] [Related]
32. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
Hensel M; Kox WJ
Acta Anaesthesiol Scand; 2000 Mar; 44(3):326-33. PubMed ID: 10714849
[TBL] [Abstract][Full Text] [Related]
33. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.
Dunn KE; Defulio A; Everly JJ; Donlin WD; Aklin WM; Nuzzo PA; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Exp Clin Psychopharmacol; 2013 Feb; 21(1):74-83. PubMed ID: 23205722
[TBL] [Abstract][Full Text] [Related]
34. The Effect of Adding Memantine to Clonidine in Reducing Withdrawal Symptoms in Opioid-Dependent Patients: A Double-Blind Randomized Controlled Trial.
Kheirabadi G; Najafian N; Khodadadi F
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):644-649. PubMed ID: 34559090
[TBL] [Abstract][Full Text] [Related]
35. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V
Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846
[TBL] [Abstract][Full Text] [Related]
36. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.
Adi Y; Juarez-Garcia A; Wang D; Jowett S; Frew E; Day E; Bayliss S; Roberts T; Burls A
Health Technol Assess; 2007 Feb; 11(6):iii-iv, 1-85. PubMed ID: 17280624
[TBL] [Abstract][Full Text] [Related]
37. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
38. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial.
Mannelli P; Patkar AA; Peindl K; Gorelick DA; Wu LT; Gottheil E
Addict Biol; 2009 Apr; 14(2):204-13. PubMed ID: 18715283
[TBL] [Abstract][Full Text] [Related]
39. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial.
Krishnan-Sarin S; O'Malley SS; Franco N; Cavallo DA; Tetrault JM; Shi J; Gueorguieva R; Pittman B; Krystal JH
Neuropsychopharmacology; 2020 Jan; 45(2):319-326. PubMed ID: 31590179
[TBL] [Abstract][Full Text] [Related]
40. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
Rothman RB; Gorelick DA; Heishman SJ; Eichmiller PR; Hill BH; Norbeck J; Liberto JG
J Subst Abuse Treat; 2000 Apr; 18(3):277-81. PubMed ID: 10742642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
